Search results for: Cell and Gene Therapies
Filter search results
New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy
20 October 2025
…the Cell and Gene Therapy Catapult The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of the cell and gene therapy industry…
The value of cell and gene therapies to the UK economy
20 October 2025
…Report, The value of cell and gene therapies to the UK economy, was commissioned and funded by the Cell and Gene Therapy Catapult, with support from Innovate UK. Download infographic…
Cell & Gene Therapies: Can We Find Innovative Ways to Pay?
10 May 2023, 9:00am
OHE experts in Boston provided insights about innovative approaches to reimbursement for cell and gene therapies The curative nature of cell and gene therapies has the potential to transform our…
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
…Advanced therapies including cell and gene therapies (CGTs) hold transformative potential for rare diseases, but their high upfront costs, uncertain long-term benefits, and small patient populations challenge payers and equitable…
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
…and involve patients and their healthcare professionals to ensure that the development and implementation of LA therapies align with patient needs, health system improvements, and societal or economic goals. The…
Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?
15 February 2023
…gene therapies receiving reimbursement and approval and might impact patients’ access to such therapies. How can we improve discounting of gene therapies? Possible approaches to overcoming the challenges posed by…
Exploring the Financial Sustainability of Gene Therapies
5 January 2021
…marketing approval and the size of the eligible patient populations will influence the total spend on gene therapies. As different gene therapies generate different kinds of value for the health…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
…TA therapies – pembrolizumab, larotrectinib, and entrectinib – to assess regulatory, health technology assessment (HTA), and reimbursement outcomes and identify barriers and possible solutions along the access pathway. The key…
Is the revised Congressional Budget Office model of new drug development fit for purpose?
6 May 2026
…portfolio-level, particularly in the early stages; and Produces headline estimates that are only averages and mask significant uncertainty. As a result, the model remains a highly simplified and unrealistic representation…